These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 21893508

  • 21. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.
    Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, Saito A, Kurosaki K, Jouo K, Koujiro M, Konishi S, Matsuoka S, Oono T, Hayakawa S, Miura M, Ushinohama H, Shibata T, Niimura I.
    Heart; 2003 Jan; 89(1):66-70. PubMed ID: 12482795
    [Abstract] [Full Text] [Related]

  • 22. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
    Roston TM, Vinocur JM, Maginot KR, Mohammed S, Salerno JC, Etheridge SP, Cohen M, Hamilton RM, Pflaumer A, Kanter RJ, Potts JE, LaPage MJ, Collins KK, Gebauer RA, Temple JD, Batra AS, Erickson C, Miszczak-Knecht M, Kubuš P, Bar-Cohen Y, Kantoch M, Thomas VC, Hessling G, Anderson C, Young ML, Cabrera Ortega M, Lau YR, Johnsrude CL, Fournier A, Kannankeril PJ, Sanatani S.
    Circ Arrhythm Electrophysiol; 2015 Jun; 8(3):633-42. PubMed ID: 25713214
    [Abstract] [Full Text] [Related]

  • 23. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.
    Hayashi M, Denjoy I, Hayashi M, Extramiana F, Maltret A, Roux-Buisson N, Lupoglazoff JM, Klug D, Maury P, Messali A, Guicheney P, Leenhardt A.
    Europace; 2012 Sep; 14(9):1344-51. PubMed ID: 22383456
    [Abstract] [Full Text] [Related]

  • 24. Risk of fatal arrhythmic events in long QT syndrome patients after syncope.
    Jons C, Moss AJ, Goldenberg I, Liu J, McNitt S, Zareba W, Qi M, Robinson JL.
    J Am Coll Cardiol; 2010 Feb 23; 55(8):783-8. PubMed ID: 20170817
    [Abstract] [Full Text] [Related]

  • 25. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G.
    N Engl J Med; 1999 Dec 16; 341(25):1882-90. PubMed ID: 10601507
    [Abstract] [Full Text] [Related]

  • 26. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
    Mazzanti A, Kukavica D, Trancuccio A, Memmi M, Bloise R, Gambelli P, Marino M, Ortíz-Genga M, Morini M, Monteforte N, Giordano U, Keegan R, Tomasi L, Anastasakis A, Davis AM, Shimizu W, Blom NA, Santiago DJ, Napolitano C, Monserrat L, Priori SG.
    JAMA Cardiol; 2022 May 01; 7(5):504-512. PubMed ID: 35353122
    [Abstract] [Full Text] [Related]

  • 27. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
    Roston TM, Cunningham TC, Sanatani S.
    Cardiol Young; 2017 Jan 01; 27(S1):S49-S56. PubMed ID: 28084961
    [Abstract] [Full Text] [Related]

  • 28. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
    van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder IM, Alings AM, Bosker HA, Bracke FA, van den Heuvel F, Waalewijn RA, Bikker H, van Tintelen JP, Bhuiyan ZA, van den Berg MP, Wilde AA.
    Circ Arrhythm Electrophysiol; 2012 Aug 01; 5(4):748-56. PubMed ID: 22787013
    [Abstract] [Full Text] [Related]

  • 29. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia.
    Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, Ferrandi C, Koolbergen DR, Odero A, Schwartz PJ.
    N Engl J Med; 2008 May 08; 358(19):2024-9. PubMed ID: 18463378
    [Abstract] [Full Text] [Related]

  • 30. Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricular arrhythmias.
    Hofferberth SC, Cecchin F, Loberman D, Fynn-Thompson F.
    J Thorac Cardiovasc Surg; 2014 Jan 08; 147(1):404-9. PubMed ID: 24268954
    [Abstract] [Full Text] [Related]

  • 31. Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
    Imberti JF, Underwood K, Mazzanti A, Priori SG.
    Heart Lung Circ; 2016 Aug 08; 25(8):777-83. PubMed ID: 26948768
    [Abstract] [Full Text] [Related]

  • 32. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Peltenburg PJ, Kallas D, Bos JM, Lieve KVV, Franciosi S, Roston TM, Denjoy I, Sorensen KB, Ohno S, Roses-Noguer F, Aiba T, Maltret A, LaPage MJ, Atallah J, Giudicessi JR, Clur SB, Blom NA, Tanck M, Extramiana F, Kato K, Barc J, Borggrefe M, Behr ER, Sarquella-Brugada G, Tfelt-Hansen J, Zorio E, Swan H, Kammeraad JAE, Krahn AD, Davis A, Sacher F, Schwartz PJ, Roberts JD, Skinner JR, van den Berg MP, Kannankeril PJ, Drago F, Robyns T, Haugaa K, Tavacova T, Semsarian C, Till J, Probst V, Brugada R, Shimizu W, Horie M, Leenhardt A, Ackerman MJ, Sanatani S, van der Werf C, Wilde AAM.
    Circulation; 2022 Feb 08; 145(5):333-344. PubMed ID: 34874747
    [Abstract] [Full Text] [Related]

  • 33. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH.
    Heart Rhythm; 2016 Feb 08; 13(2):433-40. PubMed ID: 26432584
    [Abstract] [Full Text] [Related]

  • 34. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
    Roston TM, Van Petegem F, Sanatani S.
    Curr Opin Cardiol; 2017 Jan 08; 32(1):78-85. PubMed ID: 27861184
    [Abstract] [Full Text] [Related]

  • 35. Treatment of asymptomatic catecholaminergic polymorphic ventricular tachycardia.
    Obeyesekere MN, Sy RW, Leong-Sit P, Gula LJ, Yee R, Skanes AC, Klein GJ, Krahn AD.
    Future Cardiol; 2012 May 08; 8(3):439-50. PubMed ID: 22642633
    [Abstract] [Full Text] [Related]

  • 36. Exercise-induced polymorphic ventricular tachycardia in adults without structural heart disease.
    Tan JH, Scheinman MM.
    Am J Cardiol; 2008 Apr 15; 101(8):1142-6. PubMed ID: 18394448
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Can sudden death be prevented by drugs?].
    Amann FW.
    Schweiz Rundsch Med Prax; 1990 Sep 25; 79(39):1142-8. PubMed ID: 1699258
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.